Appendix 4C Quarterly Activity Report
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2023.
Related news for (MESO)
- Stocks Taking Flight: Blaize Lands $120M APAC Deal, Kraig Labs Expands in Asia, Venu Secures $200M Financing, Pop Culture Enters Crypto, and More
- 24/7 Market News Snapshot 19 December, 2024 – Mesoblast Limited American Depositary Shares (NASDAQ:MESO)
- 24/7 Market News Snapshot 18 December, 2024 – Mesoblast Limited American Depositary Shares (NASDAQ:MESO)
- Notable 26 March 2024 Newsmakers
- FDA Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients following the Type B Meeting